These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Medicare and erythropoietin. Steinbrook R N Engl J Med; 2007 Jan; 356(1):4-6. PubMed ID: 17202449 [No Abstract] [Full Text] [Related]
3. Evolution of recombinant human erythropoietin usage in clinical practice in the United States. Is there an optimal way to use rHuEPO? Besarab A; McCrea JB ASAIO J; 1993; 39(1):11-8. PubMed ID: 8439674 [No Abstract] [Full Text] [Related]
4. Impact of the change in CMS billing rules for erythropoietin on hemoglobin outcomes in dialysis patients. Ofsthun NJ; Lazarus JM Blood Purif; 2007; 25(1):31-5. PubMed ID: 17170534 [TBL] [Abstract][Full Text] [Related]
5. Rebates for anti-anemia drugs draw response from FDA, CMS. Sipkoff M Manag Care; 2007 Jun; 16(6):17-8. PubMed ID: 17682732 [No Abstract] [Full Text] [Related]
6. Erythropoietin, the FDA, and oncology. Steinbrook R N Engl J Med; 2007 Jun; 356(24):2448-51. PubMed ID: 17568025 [No Abstract] [Full Text] [Related]
7. Kidney Failure? Dialysis is the only medical service without automatic inflation updates from Medicare. Some people are trying to change that. Zigmond J Mod Healthc; 2006 Nov; 36(44):6-7, 14-6, 1. PubMed ID: 17128943 [TBL] [Abstract][Full Text] [Related]
8. Lack of data mires Aranesp in controversy. Wadman M Nat Biotechnol; 2007 Nov; 25(11):1193. PubMed ID: 17989655 [No Abstract] [Full Text] [Related]
9. Finding a rational approach to ESA therapy--for payers and patients. Messana A Nephrol News Issues; 2007 Sep; 21(10):54, 56. PubMed ID: 17918481 [No Abstract] [Full Text] [Related]
10. Finances of the independent dialysis facility. DeOreo PB Blood Purif; 2007; 25(1):7-11. PubMed ID: 17170530 [TBL] [Abstract][Full Text] [Related]
11. Squeezing more cost and care out of dialysis: our patients would pay the price. Meyer KB; Kassirer JP Am J Med; 2002 Feb; 112(3):232-4. PubMed ID: 11893351 [No Abstract] [Full Text] [Related]
13. Medicare program; coverage of epoetin (EPO) used by competent home dialysis patients--HCFA. Final rule. Fed Regist; 1994 Jan; 59(6):1278-85. PubMed ID: 10133081 [TBL] [Abstract][Full Text] [Related]
14. Once again, ESAs are in the eye of the storm. Neumann ME Nephrol News Issues; 2013 Jan; 27(1):10. PubMed ID: 23431575 [No Abstract] [Full Text] [Related]
15. Health care payment policies: lessons from erythropoietin. Abraham PA Am J Kidney Dis; 1993 Oct; 22(4):596-7. PubMed ID: 8213802 [No Abstract] [Full Text] [Related]
16. Prescription drug pricing: the consumer perspective. Searing A N C Med J; 2003; 64(6):300-2. PubMed ID: 14983625 [No Abstract] [Full Text] [Related]
17. Medicare payment options for recombinant erythropoietin therapy. Sisk JE; Gianfrancesco FD; Coster JM Am J Kidney Dis; 1991 Oct; 18(4 Suppl 1):93-7. PubMed ID: 1928087 [TBL] [Abstract][Full Text] [Related]
18. Report from the University Healthsystem Consortium. Int J Technol Assess Health Care; 1999; 15(2):437-8. PubMed ID: 10507201 [No Abstract] [Full Text] [Related]
20. The possible effects of CMS's 'non-decision' on a national coverage decision for ESA therapy. Cotter D; Thamer M; Zhang Y Nephrol News Issues; 2011 Aug; 25(9):15-6, 18. PubMed ID: 21905526 [No Abstract] [Full Text] [Related] [Next] [New Search]